CompletedNCT03893825
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
This study evaluated the safety of TV-46000 for people with schizophrenia.
Medication studyAges 13–65Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety of TV-46000 for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 13 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Phoenix, United States · Scottsdale, United States and 80 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: April 17, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 336
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Canada, ...
- Age range
- From 13 Years to 65 Years
- Official registry ID
- NCT03893825
- Official title
Show the full official title
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia
Recruitment & locations
CompletedPhoenix, United States · Scottsdale, United States · Tucson, United States
79 more locations
- Rogers, United States
- Anaheim, United States
- Bellflower, United States
- Colton, United States
- Costa Mesa, United States
- Culver City, United States
- Glendale, United States
- La Habra, United States
- Lemon Grove, United States
- Long Beach, United States
- Montclair, United States
- Oakland, United States
- Oceanside, United States
- Orange, United States
- Pico Rivera, United States
- San Bernardino, United States
- San Diego, United States
- Torrance, United States
- Coral Gables, United States
- Hialeah, United States
- Homestead, United States
- Lake Mary, United States
- Lauderhill, United States
- Maitland, United States
- Miami, United States
- North Miami, United States
- Tampa, United States
- West Miami, United States
- Decatur, United States
- Marietta, United States
- Norcross, United States
- Chicago, United States
- Hoffman Estates, United States
- Lincolnwood, United States
- Lake Charles, United States
- Monroe, United States
- Gaithersburg, United States
- Glen Burnie, United States
- St Louis, United States
- Las Vegas, United States
- Berlin, United States
- Cedarhurst, United States
- New York, United States
- Staten Island, United States
- Hickory, United States
- Beachwood, United States
- Cincinnati, United States
- Dayton, United States
- Garfield Heights, United States
- Media, United States
- Charleston, United States
- Memphis, United States
- Houston, United States
- Irving, United States
- Plano, United States
- Richardson, United States
- Bellevue, United States
- Burgas, Bulgaria
- Kazanlak, Bulgaria
- Lovech, Bulgaria
- Novi Iskar, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Vratsa, Bulgaria
- Edmonton, Canada
- Calgary, Canada
- Vancouver, Canada
- Chatham, Canada
- Montreal, Canada
- Clermont-Ferrand, France
- Douai, France
- Nice, France
- Toulon, France
- Afula, Israel
- Ashkelon, Israel
- Haifa, Israel
- Hod HaSharon, Israel
- Ramat Gan, Israel
- Tel Aviv, Israel
Questions about this study
What did researchers investigate?
This study evaluated the safety of TV-46000 for people with schizophrenia.
Who is behind this study?
The study sponsor is Teva Branded Pharmaceutical Products R&D, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including TV-46000 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 13 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia